Skip to main navigation Skip to search Skip to main content

The role of antiviral treatment in acute hepatitis B

Research output: Contribution to journalArticlepeer-review

Abstract

Acute hepatitis B was decreasing after the policy of global hepatitis B virus (HBV) vaccination in Taiwan. However, sporadic cases of acute hepatitis B were still encountered in our daily practice. Non-vaccination, non-response or poor response to current hepatitis B vaccine may be the cause. In addition, immune-selected or antiviral selected mutant strain may also cause new HBV infection in post-vaccination era. Studies for acute hepatitis B are not as much as for chronic hepatitis B. What is the role of antiviral agent in treating acute hepatitis B? Articles involved antiviral treatments for acute hepatitis B were reviewed. These studies showed antiviral agent may be beneficial in severe acute hepatitis B. But antiviral agent may play no role for non-severe form because it may interfere normal immune reaction and also impair anti-HBs formation.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalJournal of Internal Medicine of Taiwan
Volume22
Issue number2
Publication statusPublished - Apr 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'The role of antiviral treatment in acute hepatitis B'. Together they form a unique fingerprint.

Cite this